Last reviewed · How we verify
Ce 1 ng/ml
Ce 1 ng/ml is a drug that works by
At a glance
| Generic name | Ce 1 ng/ml |
|---|---|
| Sponsor | Imam Abdulrahman Bin Faisal University |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
However, the exact mechanism of action is not well understood at this time.
Approved indications
Common side effects
Key clinical trials
- Comparison of the Effects of Total Intravenous Anaesthesia With Target-Controlled Infusion (TCI) and Inhalation Anaesthesia on Airway Complications During Extubation and in the Early Postoperative Period in Thyroidectomy Surgery (NA)
- Oxidative Stress Effects of TIVA, CIVA, and Balanced Anesthesia in VATS (NA)
- Optimal Concentration of Remifentanil for NIM Tube Intubation With Low-dose NMBA (NA)
- Preanesthetic Analgesia/Nociception Index (ANI) and Propofol Injection Pain (NA)
- Total Intravenous Anesthesia Versus Sevoflurane Anesthesia for Endovascular Thrombectomy in Acute Ischemic Stroke (NA)
- The Effect of Volatile Anesthesia and Total Intravenous Anesthesia on Shedding of the Endothelial Glycocalyx in Patients Undergoing Mastectomy and Breast Reconstruction Using Deep Inferior Epigastric Artery Perforator Free Flap (NA)
- Evaluating the Predictive Value of the Nociception Level Index NOL (NA)
- The Effect of Total Intravenous Anesthesia and Volatile Anesthesia on Shedding of the Endothelial Glycocalyx in Patients Undergoing Laparoscopic or Robotic Assisted Gastrectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ce 1 ng/ml CI brief — competitive landscape report
- Ce 1 ng/ml updates RSS · CI watch RSS
- Imam Abdulrahman Bin Faisal University portfolio CI